血清胰岛素生物测定反映1型糖尿病的胰岛素敏感性和需求
研究纳入31例成人1型糖尿病患者,采用KIRA生物测定法检测血清胰岛素受体A(IR-A)和B(IR-B)生物活性,并用高胰岛素-正葡萄糖钳夹技术评估胰岛素敏感性。结果显示空腹IR-A和IR-B生物活性与内源性葡萄糖生成率、胰岛素需求量及糖化血红蛋白呈正相关,提示其与胰岛素抵抗、高胰岛素需求及血糖控制不佳相关。
要点
- 1型糖尿病患者空腹IR-A和IR-B生物活性与胰岛素需求量呈正相关。
- 空腹IR-A和IR-B生物活性与糖化血红蛋白呈正相关。
- KIRA生物测定可评估使用胰岛素类似物患者的循环生物活性胰岛素总量。
核心结论
- 循环IR-A和IR-B生物活性与1型糖尿病的胰岛素抵抗、高胰岛素需求及血糖控制不佳相关。
研究设计与样本
- 研究纳入31例成人1型糖尿病患者,年龄45.7±1.6岁,体重指数28.8±0.7 kg/m²。
- 采用KIRA生物测定法检测血清IR-A和IR-B生物活性。
- 采用高胰岛素-正葡萄糖钳夹技术,以低胰岛素剂量(0.4 mU/kg/min持续240分钟)联合D-[3-3H]葡萄糖输注测量葡萄糖生成率(Ra)、利用率及胰岛素对脂解的作用。
主要发现
- 基线循环IR-A生物活性为53±7 pmol/L,IR-B生物活性为81±11 pmol/L。
- 与基线相比,胰岛素输注显著增加IR-A(P < 0.001)和IR-B(P < 0.001)生物活性。
- 空腹IR-A和IR-B生物活性与内源性Ra呈正相关(r = 0.44,P = 0.01和r = 0.38,P < 0.05)。
- 空腹IR-A(r = 0.43,P = 0.02)和IR-B(r = 0.47,P = 0.01)生物活性与胰岛素需求量显著相关,与糖化血红蛋白也显著相关(IR-A:r = 0.52,P = 0.002;IR-B:r = 0.48,P = 0.006)。
临床怎么用
- KIRA生物测定提供了一种工具,可在使用胰岛素类似物治疗的1型糖尿病患者群体中评估生物活性胰岛素的数量。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Insulin resistance could increase insulin requirements in type 1 diabetes (T1D). Current insulin immunoassays do not detect insulin analogs. Kinase insulin receptor (IR) activation (KIRA) bioassays specific for human IR isoforms A (IR-A) and B (IR-B) permit assessment of all circulating insulin bioactivity. We studied whether IR-A and IR-B KIRA assays are related to direct measures of insulin sensitivity or insulin doses in T1D. DESIGN: We evaluated 31 adult patients with T1D (age 45.7 ± 1.6 years, body mass index 28.8 ± 0.7 kg/m2). Serum IR-A and IR-B bioactivities were measured by KIRA bioassays. Insulin sensitivity of glucose production (Ra) was measured by the euglycemic hyperinsulinemic clamp technique in which a low insulin dose (0.4 mU/kg/min for 240 minutes) was combined with D-[3-3H] glucose infusion to measure rates of Ra and utilization and insulin action on antilipolysis from suppression of serum free fatty acids. RESULTS: Baseline circulating IR-A bioactivity was 53 ± 7 pmol/L, and IR-B bioactivity was 81 ± 11 pmol/L. Compared with baseline, insulin infusion significantly increased IR-A (P < 0.001) and IR-B (P < 0.001) bioactivities. Fasting IR-A and IR-B bioactivities were positively related to endogenous Ra (r = 0.44, P = 0.01 and r = 0.38, P < 0.05). Fasting IR-A (r = 0.43, P = 0.02) and IR-B (r = 0.47, P = 0.01) bioactivities were significantly correlated with insulin requirements and glycosylated hemoglobin (IR-A: r = 0.52, P = 0.002; IR-B: r = 0.48, P = 0.006). CONCLUSIONS: Circulating IR-A and IR-B bioactivities are associated with insulin resistance, high insulin requirements, and poor glycemic control in T1D. Measurement of IR bioactivity by KIRA assays provides a tool to assess the amount of biologically active insulin in groups of T1D patients treated with insulin analogs.
引用
- Janssen JAMJL, Llauradó G, Varewijck AJ, et al. Serum Insulin Bioassay Reflects Insulin Sensitivity and Requirements in Type 1 Diabetes. J Clin Endocrinol Metab. 2017. PMID: 28938465. doi:10.1210/jc.2017-00892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。